Takatoshi Takubo
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.
Journal: British journal of clinical pharmacology
Published: June 02, 2017
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Journal: International journal of hematology
Published: July 26, 2016
Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.
Journal: Clinical and translational science
Published: November 23, 2015
A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology
Published: November 06, 2014
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Journal: Japanese journal of clinical oncology
Published: May 01, 2014
Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Journal: Cancer science
Published: January 08, 2014
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: August 30, 2012
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: April 17, 2012
Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients.
Journal: British journal of cancer
Published: January 14, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026